指南与共识慢阻肺

COPD维持吸入治疗指南一致性的相关因素:基于人群的纵向队列研究

Factors associated with guideline-concordant maintenance inhaled medication for COPD: a population-based, longitudinal cohort study.
指南 / 共识 · Thorax · 2026-02-16

该研究基于加拿大不列颠哥伦比亚省2011–2022年行政数据,纳入71 996例新诊断COPD患者,评估与指南一致维持吸入药物启动及持续使用相关的患者与卫生系统因素。结果显示仅30.42%患者启动指南一致治疗,启动者平均覆盖天数比例为31.93%;高急性加重风险者启动率(70.4% vs 13.3%)和覆盖比例(57.33% vs 26.35%)均更高。呼吸科专科诊疗和更多门诊就诊与启动及持续使用均呈正相关。

要点

  • 仅30.42%新诊断COPD患者启动指南一致的维持吸入治疗。
  • 高急性加重风险者启动率和用药覆盖比例均高于低风险者。
  • 呼吸科专科诊疗和更多门诊就诊与更好的指南一致用药相关。

核心结论

  • COPD患者中指南一致的维持吸入药物使用率低,增加门诊和专科诊疗可支持COPD管理。

研究设计与样本

  • 基于加拿大不列颠哥伦比亚省2011–2022年行政数据的基于人群的纵向队列研究,纳入71 996例年龄≥40岁的新诊断COPD患者,平均随访6.15年(SD 2.65)。
  • 根据既往一年急性加重情况将患者分为高风险(≥2次门诊或≥1次住院急性加重)和低风险(≤1次门诊急性加重),以判定 dispensed 药物是否与指南一致。
  • 采用单独的广义线性模型评估患者、临床和卫生系统因素与指南一致药物启动及后续持续使用的关联。

主要发现

  • 30.42%的患者启动了指南一致的治疗。
  • 在启动者中,指南一致方案的平均覆盖天数比例(PDC)为31.93%。
  • 高急性加重风险患者较低风险患者更常启动指南一致方案(平均70.4% vs 13.3%),且每患者年平均PDC更高(57.33% vs 26.35%)。
  • 呼吸科专科诊疗与启动(OR 5.14,95% CI 4.88–5.41)和持续使用(OR 1.13,95% CI 1.09–1.17)指南一致药物正相关。
  • 额外门诊就诊与启动(OR 1.25,95% CI 1.24–1.26)和持续使用(OR 1.019,95% CI 1.015–1.024)指南一致药物正相关。

临床怎么用

  • 应关注新诊断COPD患者指南一致维持吸入治疗的启动和持续使用情况。
  • 增加呼吸科专科诊疗和门诊就诊机会可能改善COPD指南一致用药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite guideline recommendations, many patients with chronic obstructive pulmonary disease (COPD) do not receive or persist with guideline-concordant maintenance inhaled medications. We examined patient and health system factors associated with guideline concordance and persistence. METHODS: We conducted a population-based cohort study using administrative data from British Columbia, Canada (2011-2022). Patients aged ≥40 years with newly diagnosed COPD were included. Patients were classified as having high risk (≥2 outpatient or ≥1 inpatient exacerbation in the prior year) or low risk (≤1 outpatient exacerbation) of exacerbations, which we used to determine whether dispensed medications were concordant with guidelines. We used separate generalised linear models to evaluate the association between patient, clinical and health system factors and the initiation of guideline-concordant medications and subsequent persistence. RESULTS: We included 71 996 patients with a mean follow-up of 6.15 years (SD 2.65). 30.42% of patients initiated guideline-concordant treatment. Among those who initiated, the mean proportion of days covered (PDC) by guideline-concordant regimens was 31.93%. Patients at high risk of exacerbations initiated guideline-concordant regimens more often than those at low risk (mean 70.4% vs 13.3%) and had a higher mean PDC (57.33% vs 26.35%) per patient-year. Pulmonologist care and additional outpatient visits increased both initiation (OR 5.14, 95% CI 4.88 to 5.41 and OR 1.25, 95% CI 1.24 to 1.26, respectively) and persistence (OR 1.13, 95% CI 1.09 to 1.17 and OR 1.019, 95% CI 1.015 to 1.024, respectively) with guideline-concordant medications. CONCLUSION: Guideline-concordant use of maintenance inhaled medications is low. Increased access to outpatient and specialist care may support COPD management.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Yin, Mehareen, Sadatsafavi, et al. Factors associated with guideline-concordant maintenance inhaled medication for COPD: a population-based, longitudinal cohort study. Thorax. 2026. PMID: 40829877. doi:10.1136/thorax-2025-223544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。